Literature DB >> 17991434

Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: is BNP or NT-proBNP a useful assessment tool?

Cynthia M Balion1, Robert S McKelvie, Sonja Reichert, Pasqualina Santaguida, Lynda Booker, Andrew Worster, Parminder Raina, Matthew J McQueen, Stephen Hill.   

Abstract

OBJECTIVES: B-type natriuretic peptides are biomarkers of heart failure (HF) that can decrease following treatment. We sought to determine whether B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) concentration changes occurred in parallel to changes in other measures of heart failure following treatment.
METHODS: We conducted a systematic review of the literature for studies that assessed B-type natriuretic peptide measurements in treatment monitoring of patients with stable chronic heart failure. Selected studies had to include at least three consecutive measurements of BNP or NT-proBNP.
RESULTS: Of 4338 citations screened, only 12 met all of the selection criteria. The selected studies included populations with a wide range of heart failure severity and therapy. BNP and NT-proBNP decreased following treatment in nine studies and was associated with improvement in clinical measures of HF.
CONCLUSIONS: There was limited data to support using BNP or NT-proBNP to monitor therapy in patients with HF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991434     DOI: 10.1016/j.clinbiochem.2007.10.006

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

Review 1.  The paradox of low BNP levels in obesity.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Michele Emdin
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

2.  Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice.

Authors:  Veselin Mitrovic; Karl-Friedrich Appel; Nicolaos Proskynitopoulos; Seyfettin Dereli; Christian Wilhelm Hamm
Journal:  Clin Res Cardiol       Date:  2009-03-18       Impact factor: 5.460

3.  N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator.

Authors:  Yu Deng; Si-Jing Cheng; Wei Hua; Min-Si Cai; Ni-Xiao Zhang; Hong-Xia Niu; Xu-Hua Chen; Min Gu; Chi Cai; Xi Liu; Hao Huang; Shu Zhang
Journal:  Front Cardiovasc Med       Date:  2022-03-01

4.  The biological variation of N-terminal pro-brain natriuretic peptide in postmenopausal women with type 2 diabetes: a case control study.

Authors:  Susana González; Eric S Kilpatrick; Stephen L Atkin
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.